ATI RN
ATI Pharmacology Proctored Exam 2023
1. While teaching a client starting therapy with rituximab, which of the following findings should the nurse instruct the client to report?
- A. Dizziness
- B. Fever
- C. Urinary frequency
- D. Dry mouth
Correct answer: B
Rationale: The correct answer is B: Fever. The nurse should instruct the client to report fever as it can be an indication of an infection, which is a potential complication of rituximab therapy. Monitoring for fever is crucial to promptly address any signs of infection and ensure the client's safety during treatment. Choices A, C, and D are not typically associated with rituximab therapy and are less likely to be directly related to a serious complication requiring immediate attention.
2. A client requests information on the use of Feverfew. Which of the following responses should the nurse make?
- A. It is used to treat skin infections.
- B. It can decrease the frequency of migraine headaches.
- C. It can lessen nasal congestion in the common cold.
- D. It can relieve nausea of morning sickness during pregnancy.
Correct answer: B
Rationale: The correct response is B: Feverfew is commonly used to decrease the frequency of migraine headaches. However, it is important to note that it has not been proven to relieve an existing migraine headache. Choices A, C, and D are incorrect as Feverfew is not typically used for treating skin infections, lessening nasal congestion in the common cold, or relieving nausea of morning sickness during pregnancy.
3. A client is receiving treatment with carboplatin. Which of the following findings should the nurse monitor?
- A. Hyperglycemia
- B. Ototoxicity
- C. Hypertension
- D. Bradycardia
Correct answer: B
Rationale: Corrected Rationale: Carboplatin is known to cause ototoxicity as a serious adverse effect. It is essential for the nurse to monitor the client for any signs or symptoms of hearing loss or other auditory issues to address them promptly. Incorrect Choices Rationale: A) Hyperglycemia is not a common side effect associated with carboplatin. C) Hypertension is not a typical finding to monitor for specifically related to carboplatin treatment. D) Bradycardia is not a primary concern when monitoring a client on carboplatin.
4. A client is receiving heparin therapy. Which of the following laboratory values should the nurse monitor to evaluate the effectiveness of the therapy?
- A. PT
- B. aPTT
- C. INR
- D. Platelet count
Correct answer: B
Rationale: The corrected answer is B: aPTT. The activated partial thromboplastin time (aPTT) is the laboratory value used to monitor the effectiveness of heparin therapy. The aPTT should be maintained at 1.5 to 2 times the normal level to ensure therapeutic anticoagulation. Monitoring aPTT helps healthcare providers adjust heparin doses to achieve the desired anticoagulant effects and prevent complications such as bleeding or clotting. Choice A, PT (prothrombin time), is used to monitor warfarin therapy, not heparin. Choice C, INR (international normalized ratio), is also used to monitor warfarin therapy. Choice D, platelet count, is important for assessing the risk of bleeding, but it does not directly monitor the effectiveness of heparin therapy.
5. A client has a new prescription for Captopril. Which of the following instructions should the nurse include?
- A. Take the medication with food.
- B. Monitor your blood pressure weekly.
- C. Notify your provider if you develop a persistent cough.
- D. Avoid using salt substitutes to prevent hyperkalemia.
Correct answer: C
Rationale: Clients prescribed with Captopril, an ACE inhibitor, are at risk of developing a persistent cough as a common adverse effect. It is essential for the client to inform their healthcare provider promptly if this side effect occurs to evaluate the need for a medication change or adjustment.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access